Methods
We explored the effects of empaglifozin 10 mg once daily versus
placebo on the annualised rate of change in estimated glomerular filtration
rate (“eGFR slope”), a tertiary outcome in the EMPA-KIDNEY
trial. We studied the acute and chronic slopes (from randomization to 2
months, and from 2 months onwards respectively) separately, using shared
parameter models to estimate the latter. EMPA-KIDNEY is registered at
